• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.

作者信息

Izzi A, Messina V, Rinaldi L, Maggi P

机构信息

Department of Infectious Disease and Emergency Infectious Diseases, D. Cotugno Hospital, Azienda Ospedaliera dei Colli, Naples, Italy.

出版信息

Eur Rev Med Pharmacol Sci. 2020 May;24(10):5193-5194. doi: 10.26355/eurrev_202005_21297.

DOI:10.26355/eurrev_202005_21297
PMID:32495848
Abstract
摘要

相似文献

1
Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.社论——索磷布韦/维帕他韦联合用药对严重急性呼吸综合征冠状病毒2（COVID-19）感染具有强大的潜在活性：如何将直接作用抗病毒药物用作广谱抗病毒剂。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5193-5194. doi: 10.26355/eurrev_202005_21297.
2
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.索非布韦终止的 RNA 比瑞德西韦终止的 RNA 对 SARS-CoV-2 校对酶更具耐药性。
Sci Rep. 2020 Oct 6;10(1):16577. doi: 10.1038/s41598-020-73641-9.
3
Sofosbuvir for COVID-19 infection: A potential candidate.索磷布韦用于治疗新型冠状病毒肺炎感染：一个潜在的候选药物。
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
4
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.索非布韦作为一种治疗 SARS-CoV-2 流行的潜在替代品。
Sci Rep. 2020 Jun 9;10(1):9294. doi: 10.1038/s41598-020-66440-9.
5
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.抗 HCV，核苷酸抑制剂，重新用于 COVID-19。
Life Sci. 2020 May 1;248:117477. doi: 10.1016/j.lfs.2020.117477. Epub 2020 Feb 28.
6
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?索非布韦作为抗新冠病毒再利用的抗病毒药物：为什么我们被说服在注册/批准的临床试验中评估该药物？
Arch Med Res. 2020 Aug;51(6):577-581. doi: 10.1016/j.arcmed.2020.04.018. Epub 2020 Apr 29.
7
Type 1 interferons as a potential treatment against COVID-19.1 型干扰素作为一种对抗 COVID-19 的潜在治疗方法。
Antiviral Res. 2020 Jun;178:104791. doi: 10.1016/j.antiviral.2020.104791. Epub 2020 Apr 7.
8
Nucleotide analogues as inhibitors of SARS-CoV Polymerase.核苷酸类似物作为 SARS-CoV 聚合酶抑制剂。
Pharmacol Res Perspect. 2020 Dec;8(6):e00674. doi: 10.1002/prp2.674.
9
Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs.SARS-CoV-2 蛋白的分子研究及其与抗病毒药物的相互作用。
Viruses. 2020 Apr 14;12(4):445. doi: 10.3390/v12040445.
10
COVID-19, Arrhythmic Risk, and Inflammation: Mind the Gap!新型冠状病毒肺炎、心律失常风险与炎症：注意差距！
Circulation. 2020 Jul 7;142(1):7-9. doi: 10.1161/CIRCULATIONAHA.120.047293. Epub 2020 Apr 14.

引用本文的文献

1
Curing of chronic hepatitis C combined with coronavirus disease 2019 in a couple over 85 years old: a case series study.一对85岁以上夫妇慢性丙型肝炎合并2019冠状病毒病的治愈情况：一项病例系列研究
Front Microbiol. 2024 Jul 31;15:1438827. doi: 10.3389/fmicb.2024.1438827. eCollection 2024.
2
Promising Therapeutic Approach for SARS-CoV-2 Infections by Using a Rutin-Based Combination Therapy.芦丁基组合疗法有望成为治疗 SARS-CoV-2 感染的方法。
ChemMedChem. 2022 Jun 3;17(11):e202200157. doi: 10.1002/cmdc.202200157. Epub 2022 May 24.
3
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.
索磷布韦/维帕他韦联合治疗早期轻度至中度 COVID-19 患者的疗效和安全性。
Sci Rep. 2022 Apr 6;12(1):5771. doi: 10.1038/s41598-022-09741-5.
4
Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors.将美国食品药品监督管理局（FDA）批准的丙型肝炎病毒直接作用抗病毒药物重新用作潜在的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）蛋白酶抑制剂。
J Mol Struct. 2022 Feb 15;1250:131920. doi: 10.1016/j.molstruc.2021.131920. Epub 2021 Nov 19.
5
Sensitive Determination of SARS-COV-2 and the Anti-hepatitis C Virus Agent Velpatasvir Enabled by Novel Metal-Organic Frameworks.新型金属有机框架实现对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和抗丙型肝炎病毒药物维帕他韦的灵敏测定。
ACS Omega. 2021 Sep 30;6(40):26791-26798. doi: 10.1021/acsomega.1c04525. eCollection 2021 Oct 12.
6
What we have learned from the COVID-19 pandemic: Time to think outside the box, maybe far outside.从 COVID-19 大流行中我们所学到的：是时候跳出固有思维了，也许要远远地跳出去。
Clin Dermatol. 2021 Jan-Feb;39(1):107-117. doi: 10.1016/j.clindermatol.2020.12.020. Epub 2020 Dec 16.
7
Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.通过联合虚拟筛选和监督机器学习鉴定针对 SARS-CoV-2 冠状病毒三个靶点的新型化合物。
Comput Biol Med. 2021 Jun;133:104359. doi: 10.1016/j.compbiomed.2021.104359. Epub 2021 Mar 30.
8
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.一种纳米荧光素酶 SARS-CoV-2，可用于快速中和试验和筛选抗 COVID-19 抗感染药物。
Nat Commun. 2020 Oct 15;11(1):5214. doi: 10.1038/s41467-020-19055-7.
9
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.索非布韦终止的 RNA 比瑞德西韦终止的 RNA 对 SARS-CoV-2 校对酶更具耐药性。
Sci Rep. 2020 Oct 6;10(1):16577. doi: 10.1038/s41598-020-73641-9.